Nav: Home

Bioanalysis publishes special focus issue on 'Biomarker Assay Validation'

June 27, 2018

The Future Science Group (FSG) published journal, Bioanalysis, which is a leading MEDLINE indexed journal for bioanalysts, today announced the release of its Special Focus Issue on 'Biomarker Assay Validation (BAV) '.

This Special Focus Issue hopes to offer readers of the journal an insight into the various issues that exist surrounding the BAV, how these issues have evolved over the years, as well as the recent regulatory activities around these.

This issue was guest edited by Steven Piccoli (Neoteric) and Fabio Garofolo (Angelini Pharma).

Dr. Piccoli stated: "The issues of biomarker assay validation have evolved over the years, reflecting significant changes in thought-provoking chemotypes, steady advances in analytical technologies and a much more granular interrogatory proposed in support of precision medicine."

He continued: "In order to explore these concerns, this themed issue of Bioanalysis has been dedicated to Biomarker Assay Validation and shares with the reader scientific insight, regulatory opinion and pertinent examples of the current processes."

In this issue, parallelism assessments in LBA biomarker assay development and validation, clinical biomarker validation, the evolution of fit-for-purpose biomarker validations as well as many other important topics are discussed by experts and key opinion leaders in the biomarker field.

Another highlight of this issue is the progress update for the C-Path White Paper on the joint FDA &C-Path Initiative collaboration on analytical validation of biomarker assays used in the FDA biomarker qualification process.

Hannah Makin, one of the co-editors for Bioanalysis commented: "We are delighted to publish this Special Focus Issue, which aims to provide a glimpse into the critical questions that are raised by the issues of biomarker assay validation, as well as the recent regulatory activities surrounding these. We hope that this Special Focus Issues highlights the importance of communication between scientists, regulators, and stakeholders in order to tackle difficult medical challenges and ultimately achieve significant healthcare improvements for patients."
-end-
The full issue is available online here: http://www.future-science.com/toc/bio/10/12

The guest editors' free-access foreword article is available online here: https://www.future-science.com/doi/10.4155/bio-2018-0127

About Bioanalysis

Bioanalysis is a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to those working on the analysis of xenobiotics and biotics in biological matrices. This is, primarily, bioanalysts working in pharmaceutical research and development, clinical laboratories, clinical toxicologists, forensic toxicologists and sports doping analysts.

About Bioanalysis Zone

Since launching in 2011, Bioanalysis Zone has attracted over 7,500 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, original research exclusive interviews and commentaries. Membership is completely free of charge. Sign up online at: http://www.bioanalysis-zone.com/register.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. http://www.futuresciencegroup.com.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com.

Future Science Group

Related Bav Articles:

Bioanalysis publishes special focus issue on 'Biomarker Assay Validation'
The Future Science Group (FSG) published journal, Bioanalysis, which is a leading MEDLINE indexed journal for bioanalysts, today announced the release of its Special Focus Issue on 'Biomarker Assay Validation (BAV) '.
Registry data examines oral anticoagulant use in women, adverse events after PCI discharge
Data from the American College of Cardiology's National Cardiovascular Data Registry was the source of several published studies in recent months, including a study on predicting 30-day readmission rates for patients undergoing percutaneous coronary intervention and a study that found women were less likely to use oral anticoagulants to treat atrial fibrillation.
Study implicates 2 genetic variants in bicuspid aortic valve development
Researchers report a key protein is affected during heart valve formation, in the first genome-wide study of bicuspid aortic valve.
CNIC researchers identify a new signaling mechanism implicated in congenital aortic valve disease
The research team has demonstrated the essential role of genes encoding components of the NOTCH signaling pathway in the development of the heart valves.
Northwestern launches comprehensive program for patients with bicuspid aortic valve disease
Northwestern Memorial Hospital's Bluhm Cardiovascular Institute has been at the forefront of BAV research and treatment for years and recently launched a comprehensive program that brings together a multidisciplinary team of specialists experienced in the diagnosis and medical and surgical management of patients with BAV.
Mount Sinai releases landmark research at American College of Cardiology meeting
Mount Sinai School of Medicine researchers presented 86 abstracts and plenary sessions at the American College of Cardiology's 61st Annual Scientific Session, including groundbreaking research on aggressive statin therapy, the prevalence of unrecognized cardiovascular disease symptoms in women, and morbidity associated with non-adherence to medication after stent implantation.
First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
Clinical researchers here reported the first results of a pilot study with the anticoagulant Angiomax ® (bivalirudin) as an adjunct to catheter-based procedures in patients with severely defective aortic heart valves in whom surgery was not possible.
Study examines risk of aortic complications among patients with common congenital heart valve defect
While the incidence of the life-threatening condition of aortic dissection is significantly higher than in the general population, it remains low among patients with the congenital heart defect, bicuspid aortic valve; however, the incidence of aortic aneurysms is significantly high, according to a study in the Sept.
JCI online early table of contents: June 1, 2011
This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, June 1, 2011, in the JCI: Reducing a severe side effect of a common anticancer drug; Subdivisions reveal effective therapies in triple-negative breast cancer; Not all breast tumor cells are created equal: how to target the bad guys; Combating exhaustion in immune cells; The protein GATA5 ensures one-way traffic in the heart; and others.
People with common heart defect also more likely to have brain aneurysms
A new study shows that people with a common heart defect may also be more likely to have brain aneurysms.

Related Bav Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".